{"filing":{"accession_number":"0001664710-26-000038","cik":"0001664710","ticker":"KROS","company_name":"Keros Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-22","report_date":null,"primary_document":"kros-20260717.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1664710/000166471026000038/kros-20260717.htm"},"events":[{"id":19453,"run_id":17512,"accession_number":"0001664710-26-000038","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"The filing discloses two executive transitions: Keith Regnante's resignation as CFO effective August 3, 2026, and Annita Tanini's appointment as interim principal financial officer and principal accounting officer effective August 4, 2026. While both events occur, the principal disclosed action centers on Tanini's appointment to the CFO role, including detailed compensation arrangements ($302,300 base salary, 30% bonus target, severance terms). The filing emphasizes her qualifications and new employment agreement, making the appointment the salient event, though Regnante's departure is also disclosed.","company_name":"Keros Therapeutics, Inc.","ticker":"KROS","filing_date":"2026-07-22","form":"8-K","submitted_at":null,"items":[{"id":18546,"accession_number":"0001664710-26-000038","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses two executive transitions: Keith Regnante's resignation as CFO effective August 3, 2026, and Annita Tanini's appointment as interim principal financial officer and principal accounting officer effective August 4, 2026. While both events occur, the principal disclosed action centers on Tanini's appointment to the CFO role, including detailed compensation arrangements ($302,300 base salary, 30% bonus target, severance terms). The filing emphasizes her qualifications and new employment agreement, making the appointment the salient event, though Regnante's departure is also disclosed.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T20:02:50.189987+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":18546,"accession_number":"0001664710-26-000038","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses two executive transitions: Keith Regnante's resignation as CFO effective August 3, 2026, and Annita Tanini's appointment as interim principal financial officer and principal accounting officer effective August 4, 2026. While both events occur, the principal disclosed action centers on Tanini's appointment to the CFO role, including detailed compensation arrangements ($302,300 base salary, 30% bonus target, severance terms). The filing emphasizes her qualifications and new employment agreement, making the appointment the salient event, though Regnante's departure is also disclosed.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T20:02:50.189987+00:00","company_name":"Keros Therapeutics, Inc.","ticker":"KROS","filing_date":"2026-07-22"}]}